CTOs on the Move


 
ApexCare is a Salem, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Waltz Pharmacy Inc

Waltz Pharmacy Inc is a Camden, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alfa Aesar

Alfa Aesar, a Johnson Matthey Company, is a leading international manufacturer and supplier of research chemicals, metals and materials. With 30,000 products listed in the catalogue, Alfa Aesar is the single source for customers' chemical and material

Organigram

Founded in 2013, Organigram is a leading Canadian licensed producer, focused on producing high-quality, indoor-grown cannabis for adult recreational consumers in all provinces and the Yukon. Headquartered in Toronto, Organigram has three state-of-the-art cultivation and processing facilities in Moncton, Winnipeg and Lac-Supérieur, and its adult-use products can be found in retail outlets from coast-to-coast. Organigram`s adult-use brands include Edison, SHRED, monjour, Laurentian Cannabis, Holy Mountain, Big Bag O`Buds, Tremblant Cannabis and Trailblazer.

Perlan Therapeutics Inc

Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.